Drug

EyePoint's DURAVYU Misses Primary Endpoint in Phase III LUCIA Trial for Wet AMD – Non‑Inferiority vs. Aflibercept Not Achieved; Key Secondary Endpoints Met
Betta PharmaceuticalsClinical trial results

EyePoint’s DURAVYU Misses Primary Endpoint in Phase III LUCIA Trial for Wet AMD – Non‑Inferiority vs. Aflibercept Not Achieved; Key Secondary Endpoints Met

Betta Pharmaceuticals (SHE: 300558) announced that its partner EyePoint Pharmaceuticals (NASDAQ: EYPT) disclosed data from LUCIA, the second pivotal Phase III clinical trial evaluating EYP‑1901 (DURAVYU), an investigational vorolanib ophthalmic…

Eli Lilly's Omvoh Delivers First One‑Year Phase 3 Readout in Pediatric Ulcerative Colitis – 50 % Clinical Remission at Week 52 in SHINE‑2

Eli Lilly’s Omvoh Delivers First One‑Year Phase 3 Readout in Pediatric Ulcerative Colitis – 50 % Clinical Remission at Week 52 in SHINE‑2

AbbVie's Dual‑Targeting ABBV‑466 Outperforms Both Monotherapies in Crohn's Disease – Higher Endoscopic Remission Rates at Week 12 in TARGET‑CD Study

AbbVie’s Dual‑Targeting ABBV‑466 Outperforms Both Monotherapies in Crohn’s Disease – Higher Endoscopic Remission Rates at Week 12 in TARGET‑CD Study

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Sanofi Q3 2025 Results: 7 % Revenue Growth, Dupixent Drives Pharma Upswing
Finanical ReportsNASDAQ: SNY

Sanofi Q3 2025 Results: 7 % Revenue Growth, Dupixent Drives Pharma Upswing

Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans
Circode BioRare / orphan disease drugs

Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans

Huadong’s Mefatinib Approved by NMPA for EGFR‑Driven NSCLC
CancerHuadong Medicine

Huadong’s Mefatinib Approved by NMPA for EGFR‑Driven NSCLC

Hengrui Launches Henagliflozin Triple‑Combination Metformin for Type 2 Diabetes
DiabetesHengrui Pharmaceuticals

Hengrui Launches Henagliflozin Triple‑Combination Metformin for Type 2 Diabetes

Show More